Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...

A promising Alzheimer’s treatment failed to slow the progress of the disease, news that could dampen enthusiasm for a new ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

Circular Genomics, Inc., a leading neurological and psychiatric precision medicine company, today announced that new findings ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Researchers may be on the edge of a medical breakthrough, after finding that people with more muscle mass, but less hidden fat have healthier, younger brains.

Both microtubule-binding protein tau and RNA-binding protein TDP-43 have been associated with neurodegenerative diseases, such as Alzheimer’s disease, including in co-pathological deposition with each ...

A new study suggests that exercise can be particularly beneficial for older people at a higher risk for the disease.

A Harvard neurologist shares how many steps you should aim for each day for a healthy brain to prevent memory loss and ...

Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in ...

More than a century ago, Alois Alzheimer noted unusual changes in brain fats, which he described as "lipoid granules," along ...